Rush Street Interactive Inc vs BIO-TECHNE Corp — how do they compare? Rush Street Interactive Inc trades at $26.65 (market cap $3.12B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is far larger — about 3.6× Rush Street Interactive Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals.
| RSI | TECH | |
|---|---|---|
Market Cap | $3.12B | $11.34B |
Sector | Technology | Health |
52-Week High | $34.52 | $72.48 |
52-Week Low | $15.89 | $43.31 |
Enterprise Value | $2.79B | $11.36B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Rush Street Interactive (RSI) trades at $27.02, up 1.27% today, with a bullish technical signal from moving averages and strong institutional interest. Recent Q2 2026 results showed record revenue of $393.8 million and net income of $29.3 million, beating EPS expectations. The company raised full-year 2026 guidance, reflecting robust growth in online casino and sports betting markets. Analyst consensus is strongly bullish with a $34.75 price target, indicating 29% upside potential from current levels.
The outlook for RSI is positive, driven by accelerating revenue growth and expanding market share, but risks include intense competition and regulatory scrutiny in the gambling sector. High valuation multiples like a P/E of 87.16 suggest elevated expectations, requiring continued execution. Institutional buying, such as BlackRock's $448 million investment in Q2 2026, supports confidence, though investors should monitor margin pressures from rising marketing costs.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Trailing returns across standard periods
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →